Clinical Trial Phase 1

This trial is testing whether a rectally delivered probiotic can change the gut microbiome and promote mucosal healing in people with mild-to-moderate ulcerative colitis (and includes some Crohn's patients). If...

New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean...

Patients with UC often take multiple medicines that rely on CYP enzymes. This study is checking if afimkibart affects how those drugs are processed, which could matter for safety or dosing if the drug proceeds in...

Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical...

This trial tests etrasimod (an S1P receptor modulator) specifically in older adults with active ulcerative colitis — a group often underrepresented in IBD trials. Results could inform safety and short-term remission...

People with Crohn’s disease often have disrupted gut microbiomes; this trial tests a food-based approach (cranberry powder) that could potentially encourage beneficial bacteria and reduce inflammation, which is of direct...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...

People with Crohn's disease commonly experience menstrual cramps, but there is little trial evidence comparing common OTC pain medicines in this group. This pilot trial aims to test whether a larger randomized study is...

A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.

This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...

an investigational oral drug (PALI-2108) being developed specifically for UC and Crohn’s disease, reporting favorable Phase 1 safety and early activity and noting upcoming Phase 2 readouts. For people following new...

A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...

Fibrosis and strictures (fibrostenotic disease) are important unmet problems in Crohn’s disease with limited medical options. An investigational drug that targets PDE4 locally could potentially offer a new approach if...

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

This study tests a live Faecalibacterium prausnitzii probiotic (EXL01) as a way to prolong steroid-induced remission in Crohn’s disease, a potential new strategy to reduce relapses and steroid exposure.

Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Stricture, and Research and clinical trials.

This is the first reported organoid-based intestinal regenerative therapy entering clinical trials, which could offer a new approach for Crohn’s patients whose ulcers don’t heal with current treatments. Early-stage...

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

Perianal fistulas are a serious, hard-to-treat complication of Crohn disease. Fast Track status may speed development of a new implantable stem cell therapy that aims to close fistulas and promote local healing. Ongoing...

Patients and clinicians following new, non‑immunosuppressive approaches to UC may be interested because MB310 is an oral live‑biotherapeutic designed to induce remission and is entering clinical testing.

Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.

This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...

This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...

This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.

If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...

Cure8 found this source from pharmaceutical-technology.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original...

This notes a new oral investigational drug (Amelenodor/NX-13) in Phase I for Crohn’s and ulcerative colitis and highlights industry predictions about its chances of advancing. People with IBD may want to know about...